Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy partner for EKTERLY® (sebetralstat), an FDA-approved oral therapy for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
HAE is a life-threatening inherited genetic disorder that can affect the autoimmune system, causing recurrent episodes of severe swelling, most commonly in the limbs, face, intestines and airway. The condition is a result of low levels or improper functioning of a protein called C1 inhibitor. While minor trauma or stress could trigger an attack, swelling often occurs without a known trigger. EKTERLY is administered at the onset of an HAE attack to quickly relieve symptoms and reduce the severity and duration of the episode. It is the tenth HAE therapy to join Orsini’s portfolio.
“Orsini has been a leader in the HAE space for over 14 years, and we are deeply committed to giving patients the care they need to overcome the day-to-day struggles they face,” Darin DeCarlo, Orsini’s Chief Commercial Officer, said. “It’s our mission to ensure that no patient gets left behind, so we’re thrilled to have another way to serve the HAE community with EKTERLY.”
